Network pharmacology-based prediction of efficacy and mechanism of Myrrha acting on Allergic Rhinitis

Article information

J Korean Med. 2024;45(1):113-124
Publication date (electronic) : 2024 March 1
doi : https://doi.org/10.13048/jkm.24007
1Department of Pharmacology, School of Korean Medicine, Wonkwang University
2Hanbang Cardio-Renal Syndrome Research Center, Wonkwang University
3Research center of Traditional Korean medicine, Wonkwang University
Correspondence to: Gi-Sang Bae, Department of Pharmacology, School of Korean Medicine, Wonkwang University, 460 Iksandae-ro, Iksan, 54538 Jeonbuk, South Korea, Tel: +82-63-850-6842, E-mail: baegs888@wku.ac.kr
a

Equally contributed

Received 2024 January 15; Revised 2024 February 7; Accepted 2024 February 16.

Abstract

Objectives

Network pharmacology is an analysis method that explores drug-centered efficacy and mechanism by constructing a compound-target-disease network based on system biology, and is attracting attention as a methodology for studying herbal medicine that has the characteristics for multi-compound therapeutics. Thus, we investigated the potential functions and pathways of Myrrha on Allergic Rhinitis (AR) via network pharmacology analysis and molecular docking.

Methods

Using public databases and PubChem database, compounds of Myrrha and their target genes were collected. The putative target genes of Myrrha and known target genes of AR were compared and found the correlation. Then, the network was constructed using STRING database, and functional enrichment analysis was conducted based on the Gene Ontology (GO) Biological process and Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathways. Binding-Docking stimulation was performed using CB-Dock.

Results

The result showed that total 3 compounds and 55 related genes were gathered from Myrrha. 33 genes were interacted with AR gene set, suggesting that the effects of Myrrha are closely related to AR. Target genes of Myrrha are considerably associated with various pathways including ‘Fc epsilon RI signaling pathway’ and ‘JAK-STAT signaling pathway’. As a result of blinding docking, AKT1, which is involved in both mechanisms, had high binding energies for abietic acid and dehydroabietic acid, which are components of Myrrha.

Conclusion

Through a network pharmacological method, Myrrha was predicted to have high relevance with AR by regulating AKT1. This study could be used as a basis for studying therapeutic effects of Myrrha on AR.

Fig. 1

(A) Network of Myrrha with 55nodes and 478edges. (B) Veen-diagram of intersection targets between Myrrha network and gene sets of Allergic Rhinitis (AR). (C) Network of intersection targets of Myrrha and AR.

Fig. 2

GO biological process analysis of the intersection targets.

Fig. 3

KEGG pathway analysis of the intersection targets.

Fig. 4

The herb, compound, target and pathway network of Myrrha in the treatment of AR

Fig. 5

Molecular docking Diagrams show the interaction of AA with (A)AKT1, (B)IL6 and DA with (C)AKT1

List of Compounds from Myrrha

List of the common genes of Myrrha and Allergic Rhinitis (AR) gene set

Molecular docking results for core bioactive components of Myrrha and the corresponding target proteins

Supplementary Information

References

1. Koh Y.-I.. 2013;Diagnosis of allergic rhinitis. The Korean Journal of Medicine 85(5):452–456. https://doi.org/10.3904/kjm.2013.85.5.4521.
2. Kim C.-W.. 2012;Current update on allergic rhinitis. The Korean Journal of Medicine 82(3):298–303. https://doi.org/10.3904/kjm.2012.82.3.298.
3. Meltzer E. O.. 2016;Allergic rhinitis: Burden of illness, quality of life, comorbidities, and control. Immunology and Allergy Clinics 36(2):235–248. https://doi.org/10.1016/j.iac.2015.12.002.
4. Choi J.-H.. 2013;Allergic rhinitis and comorbidities. The Korean Journal of Medicine 85(5):457–462. https://doi.org/10.3904/kjm.2013.85.5.457.
5. Zou Q.-Y., Shen Y., Ke X., Hong S.-L., Kang H.-Y.. 2018;Exposure to air pollution and risk of prevalence of childhood allergic rhinitis: A meta-analysis. International journal of pediatric otorhinolaryngology 112(82–90) https://doi.org/10.1016/j.ijporl.2018.06.039.
6. Kim M., Kim H.-H., Kim H.-B., Ho R. Y., Park Y., Sung M., et al. 2021;Main epidemiological characteristics and natural history of pediatric allergic rhinitis. Allergy Asthma & Respiratory Diseases 9(4):203–207. https://doi.org/10.4168/aard.2021.9.4.203.
7. Alnahas S., Abouammoh N., Althagafi W., Abd-Ellatif E. E.. 2023;Prevalence, severity, and risk factors of allergic rhinitis among schoolchildren in saudi arabia: A national cross-sectional study, 2019. World Allergy Organization Journal 16(10):100824. https://doi.org/10.1016/j.waojou.2023.100824.
8. herbology, T. t. c. c. o. K. 2004. Herbology Seoul: Young Lim Sa. p. 604–606.
9. Jung D.-H., Chang S.-K., Cho C.-S., Kim C.-J.. 2006;Effects of commiphora myrrha (cm) on the monosodium urate (msu)-induced gout model in rats. The Journal of Internal Korean Medicine 27(3):715–724.
10. Kim K.-S.. 2005;Acceleration of wound healing on scald burn skin using irradiation of tdp and skin spread of myrrha. J. Exp. Biomed. Sci 11(2):243–248.
11. Jung Y. H., Roh Y. W., Chong M., Jung Y. H., Roh Y. W., Chong M.. 2022;Anti-inflammatory effects of myrrh ethanol extract on particulate matter-induced skin injury. Journal of Korean Medicine 43(3):1–15. https://doi.org/10.13048/jkm.22026.
12. Shin J. Y., Che D. N., Cho B. O., Kang H. J., Kim J., Jang S. I.. 2019;Commiphora myrrha inhibits itch-associated histamine and il-31 production in stimulated mast cells. Exp Ther Med 18(3):1914–1920. https://doi.org/10.3892/etm.2019.7721.
13. Han S. Y., Kim Y. K.. 2016;New approach for herbal formula research: Network pharmacology. Journal of Physiology & Pathology in Korean Medicine 30(6):385–396. https://doi.org/10.15188/kjopp.2016.12.30.6.385.
14. Hopkins A. L.. 2008;Network pharmacology: The next paradigm in drug discovery. Nat Chem Biol 4(11):682–690. https://doi.org/10.1038/nchembio.118.
15. Teng B., Zhang X., Yi C., Zhang Y., Ye S., Wang Y., et al. 2017;The association between ambient air pollution and allergic rhinitis: Further epidemiological evidence from changchun, northeastern china. International journal of environmental research and public health 14(3):226. https://doi.org/10.3390/ijerph14030226.
16. Lee K. S., Kim K., Choi Y. J., Yang S., Kim C. R., Moon J. H., et al. 2021;Increased sensitization rates to tree pollens in allergic children and adolescents and a change in the pollen season in the metropolitan area of seoul, korea. Pediatric Allergy and Immunology 32(5):872–879. https://doi.org/10.1111/pai.13472.
17. Lee K. S., Kim M., Kim H. H., Kim H.-B., Rha Y.-H., Park Y. M., et al. 2023;Associations between pollen and allergic rhinitis in children and adolescents. Allergy, Asthma & Respiratory Disease 11(1):3–8. https://doi.org/10.4168/aard.2023.11.1.3.
18. Kaaaci allergic rhinitis guidelines. The korean academy of asthma, allergy and clinical immunology 2022. [cited 2024 jan 11]. Available from: www.allergy.or.kr.
20. Kang C.-Y., Kim H.-J., Kim J.-H., Hwang J.-S., Lee D.-H.. 2021;Outcomes analysis for western medicine and korean medicine using the propensity score matching in allergic rhinitis: Data from the health insurance review and assessment service. The journal of Korean Medicine Ophthalmology & Otolaryngology & Dermatology 34(2) https://doi.org/10.6114/jkood.2021.34.2.053.
21. Kakli H. A., Riley T. D.. 2016;Allergic rhinitis. Primary Care: Clinics in Office Practice 43(3):465–475. https://doi.org/10.1016/j.pop.2016.04.009.
22. Kim H. H.. 2007;Allergic rhinitis, sinusitis and asthma-evidence for respiratory system integration. Clinical and Experimental Pediatrics 50(4):335–339.
23. Chung Y. S.. 2010;Allergic rhinitis and sleep-disordered breathing. Allergy, Asthma & Immunology Research 30(4):271–274.
24. Liu X., Yang Y., Li Y., Zhang Q., Wang J., Guo J., et al. 2023;Network pharmacology-based approach for investigating the role of xanthii fructus in treatment of allergic rhinitis. Chemistry & Biodiversity 20(4):e202200785. https://doi.org/10.1002/cbdv.202200785.
25. Shin M.. 2010. Clinical traditional herbalogy Seoul: Yeong. Lim Publishing. p. 748–749.
26. Ahmad A., Raish M., Ganaie M. A., Ahmad S. R., Mohsin K., Al-Jenoobi F. I., et al. 2015;Hepatoprotective effect of commiphora myrrha against d-galn/lps-induced hepatic injury in a rat model through attenuation of pro inflammatory cytokines and related genes. Pharmaceutical biology 53(12):1759–1767. https://doi.org/10.3109/13880209.2015.1005754.
27. Su S., Wang T., Duan J.-A., Zhou W., Hua Y.-Q., Tang Y.-P., et al. 2011;Anti-inflammatory and analgesic activity of different extracts of commiphora myrrha. Journal of ethnopharmacology 134(2):251–258. https://doi.org/10.1016/j.jep.2010.12.003.
28. Klemm S., Ruland J.. 2006;Inflammatory signal transduction from the fcεri to nf-κb. Immunobiology 211(10):815–820. https://doi.org/10.1016/j.imbio.2006.07.001.
29. Gibbs B. F., Räthling A., Zillikens D., Huber M., Haas H.. 2006;Initial fcɛri-mediated signal strength plays a key role in regulating basophil signaling and deactivation. Journal of allergy and clinical immunology 118(5):1060–1067. https://doi.org/10.1016/j.jaci.2006.07.022.
30. Kinet J.-P.. 1999;The high-affinity ige receptor (fcεri): From physiology to pathology. Annual review of immunology 17(1):931–972. https://doi.org/10.1146/annurev.immunol.17.1.931.
31. Li Y., Leung P. S. C., Gershwin M. E., Song J.. 2022;New mechanistic advances in fcepsilonri-mast cell-mediated allergic signaling. Clin Rev Allergy Immunol 63(3):431–446. https://doi.org/10.1007/s12016-022-08955-9.
32. Hu X., Li J., Fu M., Zhao X., Wang W.. 2021;The jak/stat signaling pathway: From bench to clinic. Signal Transduct Target Ther 6(1):402. https://doi.org/10.1038/s41392-021-00791-1.
33. Jo B. G., Bang I. S.. 2022;Anti-inflammatory effect of morinda citrifolia on lps-induced inflammation in raw 264.7 cells through the jak/stat signaling pathway. J Life Sci 32:125–134. https://doi.org/10.5352/JLS.2022.32.2.125.
34. Packard K. A., Khan M. M.. 2003;Effects of histamine on th1/th2 cytokine balance. International immunopharmacology 3(7):909–920. https://doi.org/10.1016/S1567-5769(02)00235-7.
35. Di Lorenzo A., Fernández-Hernando C., Cirino G., Sessa W. C.. 2009;Akt1 is critical for acute inflammation and histamine-mediated vascular leakage. Proceedings of the National Academy of Sciences 106(34):14552–14557. https://doi.org/10.1073/pnas.0904073106.
36. Iorga B., Herlem D., Barré E., Guillou C.. 2006;Acetylcholine nicotinic receptors: Finding the putative binding site of allosteric modulators using the “blind docking” approach. Journal of molecular modeling 12(366–372) https://doi.org/10.1007/s00894-005-0057-z.
37. Gao Y., Zhaoyu L., Xiangming F., Chunyi L., Jiayu P., Lu S., et al. 2016;Abietic acid attenuates allergic airway inflammation in a mouse allergic asthma model. Int Immunopharmacol 38:261–266. https://doi.org/10.1016/j.intimp.2016.05.029.
38. Park J., Kim J. E., Jin Y. J., Roh Y. J., Song H. J., Seol A., et al. 2023;Anti-atopic dermatitis effects of abietic acid isolated from rosin under condition optimized by response surface methodology in dncb-spread balb/c mice. Pharmaceuticals (Basel) 16(3) https://doi.org/10.3390/ph16030407.

Article information Continued

Fig. 1

(A) Network of Myrrha with 55nodes and 478edges. (B) Veen-diagram of intersection targets between Myrrha network and gene sets of Allergic Rhinitis (AR). (C) Network of intersection targets of Myrrha and AR.

Fig. 2

GO biological process analysis of the intersection targets.

Fig. 3

KEGG pathway analysis of the intersection targets.

Fig. 4

The herb, compound, target and pathway network of Myrrha in the treatment of AR

Fig. 5

Molecular docking Diagrams show the interaction of AA with (A)AKT1, (B)IL6 and DA with (C)AKT1

Table 1

List of Compounds from Myrrha

Compound Pubchem ID
Abietic Acid 10569
Dehydroabietic Acid 94391
Mansumbinone 128179
Sandaracopimaric Acid 221580

Table 2

List of the common genes of Myrrha and Allergic Rhinitis (AR) gene set

33 common Genes of Myrrha and Allergic Rhinitis
ADIPOQ, AKT1, ALOX5, BCL2, BIRC5, CASP3, CCL2, CD83, CD86, CEBPA, HSD11B1, HSD11B2, PLAU, MMP2, MMP1, FASLG, FOXO1, GPT, HMOX1, IL13, IL23A, IL5, IL6, INS, MRC1, NFATC1, NOS3, PPARG, PTGS2, SMAD3, SYK, TNF, TNFRSF11A

Table 3

Molecular docking results for core bioactive components of Myrrha and the corresponding target proteins

Components protein Binding Energies (kJ/mol) Center (x, y, z) Size (x, y, z)
Abietic Acid(AA) AKT1 −9.7 (109, 144, 96) (21, 21, 28)
Abietic Acid(AA) IL6 −7.6 (4, −2, 10) (27, 21, 21)
Dehydroabietic Acid(DA) AKT1 −9.3 (109, 144, 96) (20, 20, 28)